DOCSLIB.ORG

Microgram Journal, Vol 1, Number 7

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microgram Journal, Vol 1, Number 7 Vol. I, No. 7 Edited by Investigative ServiC('!.S Branch April, 1968 NEW BUREAU The Bureau of Drug Abuse Control joined the Federal Bureau of Nar­ cotics on April 8, 1968, to become the ne.vJ Bureau of Narcotics and Dangerous Drugs in the Department of Justice. STP CONTROLLED 4 -Methyl-2, 5-dimethoxyamphetamine, also known as 11 DOM'', or "STP", was placed under control April 2, 1968. INDIA BEEDI We have a report that students on a Florida campus are smoking "In­ dia Beedi" cigarettes in the belief that they contain peyote. According to Internal Revnue Service's Alcohol and Tobacco Tax Lab­ oratory, Washington, D.C., the cigarettes are a Government-sponsored home industry of India and are legally imported into the U.S. The cigarettes contain tobacco, hand-rolled in a witch hazel leaf ~hich has been soaked in a tobacco extract. They weigh about 0.5 gram each. The tobacco weighs about 0.14 gram and contains 3.2% nicotine. The witch hazel leaf contains about 0.5% nicotine from the tobacco extract. Cigarettes obtained by officers have been tested several times for drugs and narcotics, but have been found negative. DIPROPYLTRYPTAMINE (DPT) One of our Field Offices recently encountered this "new" drug sprayed on parsley cigarettes. The manufacturer, a research chemist, bragged that he could add a carbon to the tryptamines and stay ahead of the law indefinitely. Dipropyltryptamine is reported to be pysiologi­ cally active, but we understand that dibutyltryptamine is not. CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram MICRO-GRAM INDEX Issues No. 1 through No. 6, Volume I (November, 196 7 · - March, 1968) Subject Issue No. 3- (2 -a.minopropyl) indole (IT -290) 6 Amphetamine Tablets 5 6 Analysis Amphetamines 5 Bufotenin 2 Diethyltryptamine (DET) 2 & 4 Dimethyltryptamine (DMT) 2 Dimethyltryptamine (DMT) on parsley 2 Ibogaine 2 LSD 2 & 4 Mescal Buttons 5 Mescaline 4 Methylamphetamine 5 Methylenedioxyamphetamine · (MDA) 5 Peyote Buttons 4 Phencyclidine HCl 3 STP 1 Tetryl 5 Asthmador 2 & 4 Books 4 Bufotenine (characteristics) 2 & 4 Captagon Tablets 5 Carbona 5 Chemist, School 1, 4 &5 3- (o -chlorophenyl) -2 -methyl-4 (3H) -quinazoline 3 Clandestine Laboratories 5 & 6 Clinitest Tablets 1 Control Dates (Bufotenine,DET&Ibogaine) 2 Cupcakes (LSD) 5 From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- DET(Diethyltryptamine-characteristics 2 & 4 Dextroamphetamine Monotartrate & caffeine tablets 5 Dextromethorphan HBr Tablets 5 DMT 2, 4 & 6 DOM (See STP) Flour, LSD capsule 1 Harmine 4 Hawaiian Wood Rose 4 Ibogaine (characteristics) 2 Indopan (See IT-290) IT-290 (alph-Methyl tryptamine, 3-(2-aminopropyl) 6 indole, IT -4.03, U-14, 164E, Indopan IT-403 (See IT-290) Kat (Khat, Catha) 4 Kinortine Tablets 5 Laboratory Exam, Request for 5 LSD 2 4 6 5 Marihuana 4 MDA 5 Mecloqualone 5 Mescal Buttons (see Peyote) · M.escaline 4 6 Methamphetamine:! 6 Methylphenidate 5 From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -3- 7- (2 -1" -Methyl-2" -Phenylethylamino) -ethyl­ 5 theophyllin HCl tablets alpha -Methyl tryptamine (IT-290) 6 Methylenedioxy Amphetamine (MDA) 5 Morning Glory 3 & 4 Nubarene 5 PCP (see phencyclidine HCl) Peace Pill (see phencyclidine HCl) Peyote 4 Phencyclidine HCl ·(Peace Pill, PCP) 3 6 Psilocybin 4 6 Queen Anne's Lace 5 References 6 Ritalin (Ciba) Methylphenidate 5 & 6 Romilar Tablets 5 Sansert (Methysergide) Sandoz 1-methyl-lysergic 6 acid butanolamide School-chemists 1 & 4 Smash 4 Sominex 2 STP 1 2 Tablets Amphetamine 5 Captagon 7- (1-"Methyl-2'' -Phenyl-ethylamino 5 ethyl)-theophyllin HCl Dextroamphetamine Monotartrate and caffeine 5 Romilar (Dextromethorphan l+Br) 5 From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -4- Tetryl 5 6 r 1 Tranquinal 2 Trimethoxyarnphetarnine (TMA) 4 U-14,164E (see IT-290) Wild Carrot (see Quean Anne's Lace) From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram comprehensive list of D drugs his comprehensive list of DACA drugs has been com­ Ail drugs in this list are now covered by aU DACA regu­ T piled by the Bureau of Drug Abuse Control, Food. and lations-including record-keeping provisions and the limita­ Drug Administration. The listing includes-in alphabetical tion on the prescription order of six months and :6ve order-trade names, non-proprietary names, chemical names authorized renewals. and synonyms of DACA-controHed drugs. Products cov­ FDA still is r. ,1sidering the status of chlordiazepoxide ered are single stimulant, depressant and halludnogenic and its sr,Its and diazepam (Valium). FDA has drugs, as well as combination products. In parenthese~ postponed tl.1e effective date of the final order listing is the name the after each trade name of manufctcturer and meprobamate uPder the 1965 Drug Abuse Control Amend­ unc~mmon synonyms are followed hy chemical L<tity. Combination products submitted to BDAC with a re­ ments, pending the outcome of the petition filed by Carter­ quest for an exemption and for wbich exemption was denied Wallace in the U.S. Court of Appeals for the Fourth Circuit are denoted by a bullet ( 1!1>). Proo;lucts without a bullet in Richmond, Va. are considered to be covered under the Drug Abuse Control This listing now superce.des all previously published list­ Amendments of 1965. ings of DACA-controlled drugs. list of drugs A ll>Amagesic {Caldwell and Bloor) Amphatamin (Amphetamine Sulfate) Amaphen Tablet:> (Trimen) ;\mpl-,ate (Arnar-Ston!'>) A-884 (Methamphetamine) Amba-Dnx-TD (Moffet) ,'l.mphate (Storck) •Abactal (Massengill) A.mba-Dex (Moffet) Amphcaps (Manne) Abadex No. 1, 2 and 3.(ABA) Ambar (Robins) Amphebarb Tablets (Jabert) ~bate (Cambridge) Am bar No. 1 and 2 (Robins) "'Amphecell (Allan) •A.C.A.P. {Halsom) Ambarb Capsules (Ma\ine) Amphedase (Parke-Davis) Acotal (Prof. Drug Service) Ambi-Dex (Buffalo) Amphedex (Royce) Actemin . Ambodex (Testagar) Amphedex-TDC (Canfield) Adetate (M.S. and D.) Ambrol (Smith Miller and Patch) Amphedex-15 (Tilden-Yates) Adipan (Amphetamine Sulfate) Amcobarb Dakaps (Amco) Amphedrine (Vanpelt Brown) Adiparthrol (Amphetamine Sulfate) Amcodex Dakaps (Am co) Amphedrine-M (Vanpelt Brown) Adipex (Methamphetamine) Am-Dex (Superior) Amphedroxyn (Lilly) Adjudet Troches (lves) Amedrine (Methamphetamine) Amphe-Gum (Prof. Drug Ser-vice) Ad-Nil No. 2 (Medics) Ameritai {Merit) Amphelose (Prof. Drug Service) Ad-Nil (Medics) Amex Tablets (Pasadena) Amphemine Tablets (Prot Drug Service) Adrizine eAmfadiol (Philips Roxane) Am-Phet Capsules (M.J.) Afatin (d-Amphetamine Sulfate) Amfebarbs (Gold leaf) Am-Phet Capsules (Pharmich) Afettine (d-Amphetamine Sulfate) Amfet-Oxy-20 (Studebaker) Am-Phet Unoday PH 758 Agrypnal (Phenobarbital) Amfetamine (Amphetamine Sulfate} Am-Phet (lemmon) •Aironol (Airhart) Amgesic (Deseret) Am-Phet (Paul Maney) •Airo-Sed (Airhart) Amitrene (Normand) Ampherex (Royce) •Airotai (Airhart) •Ammonium Chloride Compound Capsules Amphet·A-Barb Extendos No. 1 (Archer- Aktedron (Elder) Taylor) <~>Aiadrine Tablets (Table Roc!<) Amobarbital Amphet-A-Barb Forte No.2 (Archer-Taylor). 8}\ladrine Tablets and Liquid (Merit) Amobarbital Sodium Amphetamine · *Aiadrine liquid (Table Roc!<) Amobese (Cole) •Amphetamine and Methylcellulose (Bari- •Aiafed (Crest) Amodex-Timed (Testagar) atric) Albemap (d-Amphetamine Sulfate) Amodex (Testagar) Amphetamine Dextra and· Amobarbital •Aibutai (Medical Arts) Amo-Dedro (Rocky Mountain) (Vitarine) Alentol (Amphetamine Sulfate) Amo-Dextrosule Jr. and Sr. (Storck) Amphetamine HCI-1 •Aiepsal ( Fougera) Amo-Dextrosule Sr. Timesule (Arnar-Stone) Amphetamine I·Giutamate-1 •Aiiasis No. 2 (Superior) Amo-Dexules Capsules (Recsei) Amphetamine Maleate-d •Aika-Nux (MacEslin) Amo-Dexules No. 1 and 2 (Recsei) Amphetamine Mucate Monobasic-! Allobarbital Amodril (North American) Amphetamine Para Aminobenzoate-1 Allobarbitone Amo-Dureide (Goodrich-Wright) Amphetamine Potassium Saccharate-d! Allodene (Amphetamine Sulfate) Amondex Timed Capsules (Testagar) f>Amphetamina Reducing Capsules No. 1 Allonal Tablets (Roche) Amo-Pellcaps No.1 and 2 (Kirkman) (Davis-Edwards) Allylbarbituric Acid Amordex (Palmedico) «'Amphetamine Reducing Capsules No. 2 Allylisobutylbarbituric Acid Amorex Injection (Mallard) (Davis-Edwards) Allyl isopropyl barbituric Acid Amosec Capsules No. 2 (Pen hurst) GAmphetamine Reducing Capsules No. 3 (Davis-Edwards) Allylisopropylmalonylurea Amosene (Ferndale) Allylisopropylmethylbarbituric Acid Amphetamine w/ Amobarbital <West-Ward) Amospan (B.S. and L) Allypropymal Amphetamine-10 (Alpha) •AI-Nai-Capsules (Cumberland) •Amo-Tran (Superior) Amphetamine-20 (Alpha} Alphetamine Capsules (Alpha) Amotrax Capsules (Jamieson-Mcl<ames) Amphetaminum (Amphetamine Sulfat~ Alphetamine 10 Capsules (Alpha) •Amozar (North American) Amphetavite Tablets (len·Tag) Alprine (Ulmer) Ampelose Tablets (Blue-line) Amphetidisin-10 (Allan) ~lubarb Elixir (Approved) •Ampha-Cei Plus (Paramount} Amphetidisin (Allan) ---Aiurate (Hoffmann-la Roche) Amphamed (Amphetamine Sulfate) Amphetocel (Lemmon) Alurate Sodium (Hoffmann-la Roche) Amphamine Tablets (!'Iaman) Amphet-0-Phen Tablets (Ruckstuhl) Alurate Verdum Elixir (Hoffmann-La Roche) Ampha-Mix Tablets (Sonnenberg) Amphet-0-Phen Tablets (Wo~ins) ®Amphetoplex (Vitamix) •Alura (Foy) AmphapleK (Pelmedico) •Aiutricol (Tutag) Ampharb (1-l<,;vey) Amphetoplex Injectable (Penhurst)
Load more

Recommended publications
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,124,126 B2 Bosse Et Al
    USOO81241.26B2 (12) United States Patent (10) Patent No.: US 8,124,126 B2 BOSse et al. (45) Date of Patent: Feb. 28, 2012 (54) PHARMACEUTICAL COMPOSITIONS (58) Field of Classification Search ........................ None See application file for complete search history. (75) Inventors: Paul Bosse, Charleston, SC (US); John Ameling, Cincinnati, OH (US); Bernard (56) References Cited Schachtel, Jupiter, FL (US); Ray Takigiku, Loveland, OH (US) U.S. PATENT DOCUMENTS 4,113,866 A 9, 1978 Lednicer et al. (73) Assignee: Charleston Laboratories, Inc., (Continued) Charleston, SC (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this CA 2665841 10/2007 patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 12/351,704 OTHER PUBLICATIONS Alexander, etal. Comparison ofondansetron and droperidol in reduc (22) Filed: Jan. 9, 2009 ing postoperative nausea and vomiting associated with patient-con trolled analgesia. Anaesthesia. Dec. 1995:50(12): 1086-8. (65) Prior Publication Data (Continued) US 2009/O175939 A1 Jul. 9, 2009 Primary Examiner — Susan Tran Related U.S. Application Data (74) Attorney, Agent, or Firm — Wilson Sonsini Goodrich & (60) Provisional application No. 61/020,139, filed on Jan. Rosati 9, 2008, provisional application No. 61/043,037, filed on Apr. 7, 2008, provisional application No. (57) ABSTRACT 61/060,758, filed on Jun. 11, 2008. Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including (51) Int. Cl. reducing or eliminating an adverse effect associated with the A6 IK9/20 (2006.01) analgesic. A6 IK9/24 (2006.01) (52) U.S.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter Et Al
    USOO9205048B2 (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter et al. (45) Date of Patent: *Dec. 8, 2015 (54) CONTROLLED RELEASE ANTIMICROBIAL (58) Field of Classification Search COMPOSITIONS AND METHODS FOR THE CPC A61 K9/0024; A61 K9/0046; A61K 31/497; TREATMENT OF OTC DSORDERS A61K 47/34 See application file for complete search history. (71) Applicants: Otonomy, Inc., San Diego, CA (US); The Regents of the University of California, Oakland, CA (US) (56) References Cited (72) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); U.S. PATENT DOCUMENTS Andrew M. Trammel, Olathe, KS (US); 4,188,373 A 2, 1980 Krezanoski Fabrice Piu, San Diego, CA (US); 4,478,822 A 10, 1984 Haslam et al. Qiang Ye, San Diego, CA (US); Luis A. 4,938,763. A 7, 1990 Dunn et al. Dellamary, San Marcos, CA (US); Carl 4,968,507 A 11/1990 Zentner et al. 5,033,252 A 7, 1991 Carter Lebel, Malibu, CA (US); Jeffrey P. 5,052,558 A 10, 1991 Carter Harris, La Jolla, CA (US) 5,292,516 A 3/1994 Viegas et al. 5,323,907 A 6/1994 Kalvelage (73) Assignees: OTONOMY, INC., San Diego, CA 5,324,519 A 6/1994 Dunn et al. (US): THE REGENTS OF THE 5,421,818 A 6/1995 Arenberg UNIVERSITY OF CALIFORNLA, 5,474,529 A 12/1995 Arenberg 5,476,446 A 12/1995 Arenberg Oakland, CA (US) 5,503,848 A 4/1996 Perbellini et al. 5,702,716 A 12/1997 Dunn et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al
    USO09526704B2 (12) United States Patent (10) Patent No.: US 9,526,704 B2 BOSse et al. (45) Date of Patent: *Dec. 27, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR A6IR 9/24 (2006.01) TREATING OR PREVENTING PAN A69/20 (2006.01) (52) U.S. Cl. (71) Applicant: LOCL Pharma, Inc., Las Vegas, NV CPC ............. A61K 9/209 (2013.01); A61 K9/2013 (US) (2013.01); A61 K9/2054 (2013.01); A61 K 3 1/167 (2013.01); A61K 31/485 (2013.01); (72) Inventors: Paul Bosse, Jupiter, FL (US); John A61K 3.1/5415 (2013.01) Ameling, Jupiter, FL (US); Bernard (58) Field of Classification Search Schachtel, Jupiter, FL (US); Ray CPC A61K 2300/00; A61K 31/167; A61K 31/485; Takigiku, Loveland, OH (US) A61K 3.1/5415: A61 K9/2054: A61 K 9/209 (73) Assignee: LOCL PHARMA, INC., Las Vegas, See application file for complete search history. NV (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,048,526 A 8/1962 Boswell This patent is Subject to a terminal dis- 3,108,046 A 10/1963 Harbit claimer. (Continued) (21) Appl. No.: 15/206.955 FOREIGN PATENT DOCUMENTS 1-1. CA 2262267 A1 8, 1999 (22) Filed: Jul. 11, 2016 DE 102005O13726 A1 9, 2006 (65) Prior Publication Data (Continued) US 2016/0317447 A1 Nov. 3, 2O16 OTHER PUBLICATIONS Related U.S. Application Data US 8.975,271, 03/2015, Oshlack et al.
    [Show full text]
  • Perspectives in Drug Discovery a Collection of Essays on the History and Development of Pharmaceutical Substances
    Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Artillerigatan 12 • SE-587 58 Linköping • Sweden E-mail: [email protected] Internet: www.rmv.se RMV-report 2010:1 ISSN 1103-7660 Copyright © 2010 National Board of Forensic Medicine and Professor Alan Wayne Jones Design and graphic original: Forma Viva, Linköping • Sweden Printed by Centraltryckeriet, Linköping • Sweden, October 2010 Contents Preface Introduction 1. The First Sedative Hypnotics . 13 2. The Barbiturates ......................... 19 3. The Benzodiazepines ..................... 25 4. Narcotic Analgesics . 31 5. Central Stimulant Amines . 39 6. The First Antidepressants .................. 45 7. Antipsychotic Medication ................. 51 8. Aspirin and Other NSAID .................. 59 9. General Anesthetics . 65 10. SSRI Antidepressants . 71 11. Histamine Antagonists .................... 79 12. Anticonvulsants ......................... 87
    [Show full text]
  • Wo 2009/132050 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132050 A2 (51) International Patent Classification: 61/101,1 12 29 September 2008 (29.09.2008) US A61K 39/395 (2006.01) A61K 47/34 (2006.01) 61/140,033 22 December 2008 (22. 12.2008) US A61P 27/16 (2006.01) A61K 9/06 (2006.01) 61/160,233 13 March 2009 (13.03.2009) US (21) International Application Number: (71) Applicants (for all designated States except US): OTON- PCT/US2009/041320 OMY, INC. [US/US]; 5626 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). THE REGENTS OF THE (22) International Filing Date: UNIVERSITY OF CALIFORNIA [US/US]; 1111 2 1 April 2009 (21 .04.2009) Franklin Street, 12th Floor, Oakland, CA 94607 (US). (25) Filing Language: English (72) Inventors; and (26) Publication Language: English (75) Inventors/Applicants (for US only): LICHTER, Jay [US/US]; P.O. Box 676244, Rancho Santa Fe, CA 92067 (30) Priority Data: (US). VOLLRATH, Benedikt [DE/US]; 4704 Niagara 61/046,543 2 1 April 2008 (21 .04.2008) US Avenue, San Diego, CA 92107 (US). TRAMMEL, An¬ 61/048,878 29 April 2008 (29.04.2008) US drew, M. [US/US]; 12485 South Alden Circle, Olathe, 61/127,7 13 14 May 2008 (14.05.2008) us KS 66062 (US). DURON, Sergio, G. [US/US]; 1605 61/055,625 23 May 2008 (23.05.2008) us Neale Street, San Diego, CA 92103 (US).
    [Show full text]
  • Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants
    Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants Author Sirdaarta, Joseph P Published 2016 Thesis Type Thesis (PhD Doctorate) School School of Natural Sciences DOI https://doi.org/10.25904/1912/1565 Copyright Statement The author owns the copyright in this thesis, unless stated otherwise. Downloaded from http://hdl.handle.net/10072/365567 Griffith Research Online https://research-repository.griffith.edu.au Griffith University Phytochemical study and anticancer potential of high antioxidant Australian native plants Principal supervisor: Dr Ian Edwin Cock Co-supervisor: Dr Sarah Ashmore By Joseph P Sirdaarta B. Food Science and Nutrition (Hons) School of Natural Sciences Griffith University Submitted in fulfilment of the requirements of the degree of Doctor of Philosophy On the April 11th 2016 Chapter 1 1 | P a g e Statement of Originality This work, entitled Phytochemical study and anticancer potential of high antioxidant Australian native plants, has not previously been submitted for a degree in any university. To the best of my knowledge and belief, the thesis contains no material previously published or written by another person except where due reference is made in the thesis itself. Joseph P Sirdaarta April 11th, 2016 Chapter 1 2 | P a g e Acknowledgements I would like to take this opportunity to thank the Lord Jesus Christ for giving me this opportunity to pursue my PhD. He has all my gratitude for his provisions and support through trying times. Furthermore, I would like to thank Griffith University for offering me the opportunity through scholarships to complete the program. I would like to thank my supervisors Dr Ian Cock and Dr Sarah Ashmore for their help and guidance.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,603.796 B2 Lichter Et Al
    US0096.03796 B2 (12) United States Patent (10) Patent No.: US 9,603.796 B2 Lichter et al. (45) Date of Patent: *Mar. 28, 2017 (54) CONTROLLED RELEASE ANTIMICROBIAL A63L/43 (2006.01) COMPOSITIONS AND METHODS FOR THE A6II 3/522 (2006.01) TREATMENT OF OTC DISORDERS A 6LX 3/573 (2006.01) A63L/7036 (2006.01) (71) Applicants: Otonomy, Inc., San Diego, CA (US); (52) U.S. Cl The R ts of the University of AV e. we (NEON y O CPC .......... A61K 9/0046 (2013.01); A61K 9/0019 s s (2013.01); A61K 9/0024 (2013.01); A61K 9/06 (72) Inventors: Jay Lichter, San Diego, CA (US); (2013.01); A61K 9/10 (2013.01); A61K 9/1641 Andrew M. Trammel, Olathe, KS (2013.01); A61K 31/43 (2013.01); A61 K (US); Fabrice Piu, San Diego, CA 3 1/496 (2013.01); A61 K3I/522 (2013.01); (US); Qiang Ye, San Diego, CA (US); A6 IK3I/573 (2013.01); A61K 3 1/7036 Luis A. Delianary, San Marcos, CA (2013.01); A61K 47/02 (2013.01); A61K 47/10 (US); Carl Lebel Malibu CA (US); (2013.01); A61K 47/34 (2013.01); A6 IK 8/042 Jeffrey P. Harris, La Jolla, CA (US) (2013.01); A61 K 9/14 (2013.01) (58) Field of Classification Search (73) Assignees: OTONOMY, INC., San Diego, CA CPC ... A61K 31/43; A61K 31/496; A61K 31/522; (US): THE REGENTS OF THE A61K 3 1/573; A61K 3 1/7036; A61 K UNIVERSITY OF CALIFORNIA, 47/02: A61K 47/10; A61K 47/34: A61 K Oakland, CA (US) 8/042: A61 K9/0019; A61K 9/0024; A61 K9/0046; A61K 9/06; A61 K9/10: (*) Notice: Subject to any disclaimer, the term of this A61K 9/14: A61 K 9/1641 patent is extended or adjusted under 35 See application file for complete search history.
    [Show full text]
  • Thermotropic Icy Road Sign with Light Scattering and Fluorescence Response
    Thermotropic Icy Road Sign with Light Scattering and Fluorescence Response a a a a Received 8th April 2021, Joshua R. Booth,† Robert A. Young,† Andrés N. Richards Gonzales, Zachary J. Meakin, Corinna M. Preuss-Weber,a,b Ross W. Jaggersa and SteFan A. F. Bon*a Prototypes of flexible, electricity-free, ice warning signs for roads and pavements have been developed. A thermotropic response in the form of an upper critical solution (UCST) type phase separation targeted near the freezing point of water manifests itself through light scattering as a clear-to-opaque transition. It is simultaneously amplified by an enhanced photoluminescence effect. The conceptual road sign application is a multi-lamellar flexible strip with an active layer of a polystyrene-based solution. The solvent is a plasticizer, here either dioctylphthalate (DOP) or its alternative 1,2-cyclohexane dicarboxylic acid diisononyl ester (DINCH). A collection of styrene-based macromolecules were made by free radical (co)polymerization, varying molecular weight and monomer feed composition. UCST type phase diagrams for the polymer solutions were constructed from cloud point data measured by a bespoke photographic set-up, in which up to 30 samples were measured simultaneously using both light scattering, that is opacity, and fluorescence. For the latter, the concept of restricted motion enhanced photoluminescence, often referred to as aggregation-induced emission (AIE), was used. Polystyrene labelled with tetraphenylethylene (TPE) was used for this. The contrast between ‘ON’ and ‘OFF’ states in the protoype ice warning signs was optimized by tuning the polymer concentration and the active layer thickness. Our prototype signs show full reversibility over many temperature cycles.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.433,625 B2 Bosse Et Al
    USOO9433625B2 (12) United States Patent (10) Patent No.: US 9.433,625 B2 BOSse et al. (45) Date of Patent: *Sep. 6, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR (52) U.S. Cl. TREATING OR PREVENTING PAN CPC ........... A61K 3.1/5415 (2013.01); A61K 9/209 - - - (2013.01); A61 K9/2054 (2013.01); A61 K (71) Applicant: 19. Pharma, Inc., Las Vegas, NV 31/167 (2013.01); A61K 31/485 (2013.01) (58) Field of Classification Search (72) Inventors: Paul Bosse, Jupiter, FL (US); John CPC ........... A61K 2300/00; A61K 31/167: A61 K Ameling, Cincinnati, OH (US); 31/485; A61K 3.1/5415: A61 K9/2054; Bernard Schachtel, Jupiter, FL (US); A61 K9/209 Ray Takigiku, Loveland, OH (US) See application file for complete search history. (73) Assignee: LOCL PHARMA, INC., Las Vegas, (56) References Cited NV (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 3,048,526 A 8, 1962 Boswell U.S.C. 154(b) by 0 days. 3,108,046 A 10, 1963 Harbit This patent is Subject to a terminal dis- (Continued) claimer. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/244,455 CA 2262267 A1 8/1999 (22) Filed1C Apr. 3, 2014 DE 102005O13726 A1 9, 2006 pr. 5, (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2014/O3O8349 A1 Oct. 16, 2014 O O U.S. Appl. No. 14/683,886, filed Apr. 10, 2015, Bosse et al. Related U.S. Application Data (Continued) (63) Continuation of application No. 12/967,423, filed on i is: .
    [Show full text]
  • The Barbiturates in Forensic Chemistry Dissertation
    THE BARBITURATES IN FORENSIC CHEMISTRY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy- in the Graduate School of The Ohio State University EQr GWENDOLYN BERTHA CARSON, B« S., M* A* The Ohio State University 195U Approved by* Department of Physiological Chemistry ___________ i TABLE OP CONTENTS page A« Introduction 1 B» Historical 1. The Barbiturates ---------------- 2 2* Barbiturate Poisoning - - -------------------- U a) Deaths due to Barbiturates in Pour Counties and the United States - - ------ ----- 11 b) Doses of Barbiturates in Grains - - -- - - 16 3* Barbiturate Regulations------- - ------------ 21 C. Isolation of the Barbiturates ----- --- - - --- - 2h D» Qualitative Tests for Barbiturates ----- — - ---- 26 E. Quantitative Methods for Barbiturates -------- 28 F* Examination of Tissues --- — 30 1# Degradation Products of Barbiturates ------ 3 1 2a Percent Recovery of Unchanged Barbiturates - - - 3^ G. Experimental Procedures --------------- 35 1* Effect of 5$ Potassium Hydroxide on Barbiturates- 36 2 . Effect of 20$ Acetic Acid on Barbiturates - - - - 38 3. Effect of Water on Salts of Barbituric Acids - - 38 k» Barbiturates Extracted from Liver with 5$ Potassium Hydroxide - — ___ ip. 5. Barbiturates Extracted from Liver with 20$ Acetic A c i d ------------------------------- Hi 6 . Barbiturates Extracted from Liver at pH 1 0 HU 7. Refractive Indices of Barbiturates - ------- H6 8 . Barbiturate-Cyanide Reaction ---------------- 50 9» Effect of Atmospheric Conditions on Barbiturates-
    [Show full text]
  • 2019 BES/Separation Science Research PI Meeting
    TITLE PAGE Program and Abstracts for the 2019 BES/Separation Science Research PI Meeting Gaithersburg Marriott Washingtonian Center 9751 Washingtonian Boulevard Gaithersburg, Maryland, 20878 September 9 – 11, 2019 The research grants and contracts described in this document are supported by the U.S. Department of Energy, Office of Science/Basic Energy Sciences, as part of the Separation Science Program within the Chemical Sciences, Geosciences and Biosciences Division. i FOREWORD This abstract booklet provides a record of the 2019 U.S. Department of Energy (DOE) contractors’ meeting in Separation Science. This meeting, held at the Marriott Washingtonian Hotel in Gaithersburg, Maryland on September 9 – 11, 2019, was sponsored by the Chemical Sciences, Geosciences and Biosciences Division of the Office of Basic Energy Sciences (BES). The purpose of the meeting was to accelerate research progress through collegial interaction. The objectives of the meeting were to develop a common understanding of researchers' activities at the time of the meeting; to maximize potential for collaborative exchange among research groups; to identify the scientific needs of the research community; and to discuss areas for future research directions. The agenda has oral presentations delivered by a number of the Principle Investigators (PIs), as well as an evening poster session. In this way, all PIs within the BES Separation Science Program presented their most recent work that was supported by the program. With ample time for discussion and interactions, this meeting was focused on the exchange of information and building of collaborations; rather than a formal review of researchers’ achievements or a forum to deliberate and choose future directions for the program.
    [Show full text]